Does CB-1 in hepatic stellate cells contribute to liver fibrosis?

被引：4

作者：

Lotersztajn, Sophie ^{[1
]}

Mallat, Ariane ^{[1
]}

机构：

[1] Univ Paris, INSERM, U1149, Ctr Rech lInflammat CRI,Lab Excellence Inflamex, F-75018 Paris, France

来源：

JOURNAL OF CLINICAL INVESTIGATION | 2022年 / 132卷 / 01期

关键词：

D O I：

10.1172/JCI155413

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

引用

页数：2

共 4 条

[1] Cannabinoid signaling and liver therapeutics [J].

Mallat, Ariane ;

Teixeira-Clerc, Fatima ;

Lotersztajn, Sophie .

JOURNAL OF HEPATOLOGY, 2013, 59 (04) :891-896

[2] The peripheral CB1 receptor antagonist JD5037 attenuates liver fibrosis via a CB1 receptor/β-arrestin1/Akt pathway [J].

Tan, Siwei ;

Liu, Huiling ;

Ke, Bilun ;

Jiang, Jie ;

Wu, Bin .

BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (12) :2830-2847

[3] CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis [J].

Teixeira-Clerc, Fatima ;

Julien, Boris ;

Grenard, Pascale ;

Van Nhieu, Jeanne Tran ;

Deveaux, Vanessa ;

Li, Liying ;

Serriere-Lanneau, Valerie ;

Ledent, Catherine ;

Mallat, Ariane ;

Lotersztajn, Sophie .

NATURE MEDICINE, 2006, 12 (06) :671-676

[4] Cannabinoid receptor 1 signaling in hepatocytes and stellate cells does not contribute to NAFLD [J].

Wang, Simeng ;

Zhu, Qingzhang ;

Liang, Guosheng ;

Franks, Tania ;

Boucher, Magalie ;

Bence, Kendra K. ;

Lu, Mingjian ;

Castorena, Carlos M. ;

Zhao, Shangang ;

Elmquist, Joel K. ;

Scherer, Philipp E. ;

Horton, Jay D. .

JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (22)

← 1 →